Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
Status:
Terminated
Trial end date:
2016-12-23
Target enrollment:
Participant gender:
Summary
The study assessed the safety and the dose of the combination of INC280 and buparlisib
(BKM120), as well as the anti-tumor activity of the combination, in patients with recurrent
glioblastoma with PTEN mutations, homozygous deletion of PTEN or PTEN negative by IHC. In
addition, the anti-tumor activity of INC280 single agent should have been assessed in
patients with recurrent glioblastoma with c-Met alteration.